Showing 8971-8980 of 9351 results for "".
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Geneticists Research Cleft Palate and Skin Deformitieshttps://practicaldermatology.com/news/20130614-geneticists_research_cleft_palate_and_skin_deformities/2459514/Scientists at Cold Spring Harbor Laboratory (CSHL) solved the mystery of why some infants are born with cleft palate and major deformities of the skin and limbs, while other infants with the same genetic mutation bear little or no sign of the illness, called Ectodactyly, Ectodermal dysplasia, Clefti
- Steve Perry Undergoes Cancer Surgeryhttps://practicaldermatology.com/news/20130611-steve_perry_undergoes_cancer_surgery/2459515/Former Journey singer Steve Perry had a cancerous mole on his right cheek removed recently. Test results found it positive for melanoma. Perry had to undergo two procedures to rid his skin of all of the cancer cells, according to his physicians, and no further treatment will be necessary.
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with moder
- JUVÉDERM VOLUMA™ XC Receives Unanimous Recommendation from FDA Panelhttps://practicaldermatology.com/news/20130514-juvderm_voluma_xc_receives_unanimous_recommendation_from_fda/2459545/The US Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augme
- Outrun the Sun Partners with Girls on the Run International for Sun Safetyhttps://practicaldermatology.com/news/20130513-outrun_the_sun_partners_with_girls_on_the_run_international_for_sun_safety/2459547/Outrun the Sun, Inc. and Girls on the Run International recently partnered up to provide sun safety education for Girls on the Run participants across America and Canada. This year, t
- Free Skin Health Screenings This Weekendhttps://practicaldermatology.com/news/20130510-free_skin_health_screenings_this_weekend/2459549/In the interest of Skin Cancer Awareness Month, Sam's Clubs nationwide are offering free skin health screenings on Saturday, May 11 from 11am-3pm to members and non members. Those screened are being encouraged to take results to a dermatologist to get proper treatment and advice after their exams. T
- Me Smooth Debuts on QVChttps://practicaldermatology.com/news/20130429-me_smooth_debuts_on_qvc/2459557/Syneron Beauty Inc. introduced its new me smooth at-home professional hair removal system on QVC this week. The device includes a travel bag and an additional elos cartridge to deliver effective removal of unwanted hair for all skin tones, accordi
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Obagi Fate Uncertain as New Details Emergehttps://practicaldermatology.com/news/20130403-obagi_fate_uncertain_as_new_details_emerge/2459573/Following a bidding war with rival Merz Pharma Group, Valeant Pharmaceuticals appears set to acquire Obagi Medical Products. Valeant's original offer came in March, when the company announced that it would acquire Obagi at $19.75 per share, in a deal worth approximately $344 million. Then, in early